Ten companies raised a combined $1.6 billion in the most active week of the 2017 IPO market. Texas community bank CBTX took the top spot with a 10% pop, which is still below the long term historical average of 13%. The week featured three...read more
InflaRx, which is developing an antibody for rare autoimmune and inflammatory diseases, raised $100 million by offering 6.7 million shares at $15, the midpoint of the $14 to $16 range. Insiders are buying $40 million (40% of the deal) on the offering. InflaRx...read more
An active 4Q17 powers ahead with 11 IPOs scheduled to raise $2.0 billion in the coming week. That would make it the IPO market's busiest week of the year. The activity level is unsurprising given the 32 new filings in October, a two-year high. We also expect a...read more
Apellis Pharmaceuticals, which is developing a novel protein inhibitor for autoimmune and inflammatory diseases, announced terms for its IPO on Monday. The Crestwood, KY-based company plans to raise $150 million by offering 10.7 million shares at a price...read more
US IPO Weekly Recap: 10 companies go public in the busiest week of 2017
Ten companies raised a combined $1.6 billion in the most active week of the 2017 IPO market. Texas community bank CBTX took the top spot with a 10% pop, which is still below the long term historical average of 13%. The week featured three...read more
Rare disease biotech InflaRx prices IPO at $15 midpoint
InflaRx, which is developing an antibody for rare autoimmune and inflammatory diseases, raised $100 million by offering 6.7 million shares at $15, the midpoint of the $14 to $16 range. Insiders are buying $40 million (40% of the deal) on the offering. InflaRx...read more
US IPO Week Ahead: China's #2 search engine leads busiest week of 2017 with 11 IPOs
An active 4Q17 powers ahead with 11 IPOs scheduled to raise $2.0 billion in the coming week. That would make it the IPO market's busiest week of the year. The activity level is unsurprising given the 32 new filings in October, a two-year high. We also expect a...read more
Immunotherapy biotech Apellis Pharmaceuticals sets terms for $150 million IPO
Apellis Pharmaceuticals, which is developing a novel protein inhibitor for autoimmune and inflammatory diseases, announced terms for its IPO on Monday. The Crestwood, KY-based company plans to raise $150 million by offering 10.7 million shares at a price...read more